COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2021-08-13Est. Completion: 2023-06-22
Enrollment target: 258 participants
Locations
UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
Yale University School of Medicine: Rheumatology, Allergy & Immunology, New Haven, Connecticut, United States
The Emory Clinic: Division of Rheumatology, Atlanta, Georgia, United States
Indiana University Medical Center, Riley Hospital for Children, Indianapolis, Indiana, United States
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Boston, Massachusetts, United States
Boston Children's Hospital: Department of Pediatrics, Rheumatology Program, Boston, Massachusetts, United States
Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology, Boston, Massachusetts, United States
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States
Washington University School of Medicine in St. Louis: Division of Rheumatology, St Louis, Missouri, United States
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset, New York, United States
Feinstein Institute for Medical Research, Manhasset, New York, United States
Other microbiome trials you might be interested in